Anselmo Aaron C, Mitragotri Samir
Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina.
John A Paulson School of Engineering and Applied Sciences Harvard University, Wyss Institute of Biologically Inspired Engineering Cambridge Massachusetts.
Bioeng Transl Med. 2019 Sep 5;4(3):e10143. doi: 10.1002/btm2.10143. eCollection 2019 Sep.
Nanoparticle drug delivery systems have been used in the clinic since the early 1990's. Since that time, the field of nanomedicine has evolved alongside growing technological needs to improve the delivery of various therapeutics. Over these past decades, newer generations of nanoparticles have emerged that are capable of performing additional delivery functions that can enable treatment via new therapeutic modalities. In the current clinical landscape, many of these new generation nanoparticles have reached clinical trials and have been approved for various indications. In the first issue of in 2016, we reviewed the history, current clinical landscape, and clinical challenges of nanoparticle delivery systems. Here, we provide a 3 year update on the current clinical landscape of nanoparticle drug delivery systems and highlight newly approved nanomedicines, provide a status update on previous clinical trials, and highlight new technologies that have recently entered the clinic.
自20世纪90年代初以来，纳米颗粒药物递送系统已应用于临床。从那时起，随着改善各种治疗药物递送的技术需求不断增长，纳米医学领域也在不断发展。在过去几十年中，新一代纳米颗粒不断涌现，它们能够执行额外的递送功能，从而通过新的治疗方式实现治疗。在当前的临床环境中，许多新一代纳米颗粒已进入临床试验阶段，并已获批用于各种适应症。在2016年的第一期杂志中，我们回顾了纳米颗粒递送系统的历史、当前临床环境以及临床挑战。在此，我们提供纳米颗粒药物递送系统当前临床环境的三年更新情况，重点介绍新获批的纳米药物，提供之前临床试验的进展更新，并突出最近进入临床的新技术。
